6 Cardiology Headlines You Missed in July 2026
July saw some of the biggest FDA approvals so far in 2026 – catch up on what you might have missed!
After a quiet June, cardiology came roaring back for a full slate in July 2026. The US Food and Drug Administration produced a slew of approvals for key devices and medications in dyslipidemia and heart failure (HF), while the SYMPHONY-PE trial demonstrated the value of early mechanical thrombectomy in improving cardiovascular health without impacting safety in patients with pulmonary embolism. Additionally, the American Heart Association (AHA) and the American College of Cardiology (ACC) released the first-ever clinical treatment guidelines for cardiovascular-kidney-metabolic (CKM) syndrome, paving a way forward for the treatment of this prolific condition.